ABCL
NASDAQAbCellera Biologics Inc.
Price$6.46+0.33 (+5.38%)
01:30 PM07:45 PM
News · 26 weeks38-20%
2026-01-182026-07-12
Mix2890d
- Insider9(32%)
- SEC Filings8(29%)
- Earnings4(14%)
- Other3(11%)
- Analyst2(7%)
- Leadership2(7%)
Latest news
25 items- PRAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
- PRAbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026AbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For m
- ANALYSTAbCellera Biologics upgraded by The Benchmark Company with a new price targetThe Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $11.00
- INSIDERSEC Form 4 filed by Director Seely Lynn4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 3 filed by new insider Seely Lynn3 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Director Sandor Victor4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Appoints Dr. Lynn Seely to its Board of DirectorsAbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women’s health. I am pleased to welcome her to AbCellera’s Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Dr. Seely’s experience as a biopharmaceutical executive and board member includes an extensive background in strategic, clinical, and commercial execution, which are highly relevant to AbCellera's work in discovering and developing impactful a
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesThe collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and AbCellera (NASDAQ:ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (G
- INSIDERSEC Form 4 filed by Director Hayden Michael R4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Director Quake Stephen4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERSEC Form 4 filed by Director Montalbano John S.4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- INSIDERSEC Form 3 filed by new insider Sandor Victor3 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Appoints Dr. Victor Sandor to its Board of DirectorsAbCellera (NASDAQ:ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I am pleased to welcome Dr. Sandor to AbCellera's Board of Directors and look forward to working with him." Before its acquisition by Pfizer Inc., Dr. Sandor served as Chief Medical Officer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array
- INSIDERChief Financial Officer Booth Andrew exercised 250,000 shares at a strike of $0.19, increasing direct ownership by 128% to 445,600 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERDirector Montalbano John S. bought $95,400 worth of shares (20,000 units at $4.77), increasing direct ownership by 9% to 241,000 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form 10-Q filed by AbCellera Biologics Inc.10-Q - AbCellera Biologics Inc. (0001703057) (Filer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. Ended Q1 2026 with total available liquidity of approximately $655 million. AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635. ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dol
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.SCHEDULE 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
- PRAbCellera to Present at Upcoming Investor Conferences in May and June 2026AbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026 Jefferies Global Healthcare Conference in New York, June 4, 2026 A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunolog
- ANALYSTCantor Fitzgerald initiated coverage on AbCellera Biologics with a new price targetCantor Fitzgerald initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $7.00
ABCL FAQ
7 questionsWhat does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.Where does ABCL stock trade?
AbCellera Biologics Inc. (ABCL) is listed on NASDAQ.What sector and industry is ABCL in?
AbCellera Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbCellera Biologics Inc. go public?
AbCellera Biologics Inc. (ABCL) completed its IPO in 2020.What are analysts saying about ABCL?
AbCellera Biologics Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy with a $1100.00 price target on 2026-07-07. Recent price targets range from $400.00 to $1100.00.What companies are similar to ABCL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABCL side-by-side with any of them on Quantisnow.How can I track ABCL on Quantisnow?
Quantisnow aggregates AbCellera Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABCL to receive live email and push alerts on every new disclosure.